GOBBI, PAOLO
 Distribuzione geografica
Continente #
NA - Nord America 1.232
EU - Europa 840
AS - Asia 666
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
AF - Africa 1
SA - Sud America 1
Totale 2.749
Nazione #
US - Stati Uniti d'America 1.225
CN - Cina 591
IE - Irlanda 272
UA - Ucraina 146
FI - Finlandia 129
DE - Germania 96
SE - Svezia 76
SG - Singapore 63
IT - Italia 44
GB - Regno Unito 34
BE - Belgio 14
CZ - Repubblica Ceca 8
CA - Canada 7
EU - Europa 6
FR - Francia 6
IN - India 4
RU - Federazione Russa 4
AU - Australia 3
MK - Macedonia 3
JP - Giappone 2
NL - Olanda 2
RO - Romania 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BR - Brasile 1
DK - Danimarca 1
GR - Grecia 1
MY - Malesia 1
PT - Portogallo 1
SA - Arabia Saudita 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 2.749
Città #
Chandler 298
Dublin 272
Jacksonville 215
Nanjing 178
Beijing 81
Ashburn 74
Boardman 74
Nanchang 69
Ann Arbor 59
Lawrence 49
Princeton 49
Singapore 46
Wilmington 46
Hebei 45
Jiaxing 40
Medford 40
Shenyang 39
Helsinki 38
Changsha 34
Hangzhou 24
Tianjin 24
New York 18
Brussels 14
Shanghai 14
Des Moines 12
Milan 11
Woodbridge 11
Seattle 10
Brno 8
Norwalk 8
Fairfield 7
Kunming 6
Pavia 6
Los Angeles 5
Munich 5
Verona 5
Guangzhou 4
Houston 4
San Genesio Ed Uniti 4
Andover 3
Cambridge 3
Haikou 3
Jinan 3
Ningbo 3
Orange 3
Toronto 3
Washington 3
Borås 2
Chicago 2
Dallas 2
Dearborn 2
Falkenstein 2
Frankfurt am Main 2
Lanzhou 2
Orlando 2
Philadelphia 2
San Francisco 2
Taizhou 2
Albert Park 1
Atlanta 1
Auburn Hills 1
Berlin 1
Boston 1
Bridgeport 1
Bucharest 1
Canberra 1
Cedar Knolls 1
Cupertino 1
Dubai 1
Edmonton 1
Harbin 1
Henderson 1
Hyderabad 1
Jiaozuo 1
Jinshan 1
Kharkov 1
Las Vegas 1
Lonigo 1
Markham 1
Modena 1
Monsummano Terme 1
Naples 1
Ottawa 1
Pune 1
Riyadh 1
Rockville 1
Selangor 1
Shenzhen 1
Sofia 1
Southend 1
Stockholm 1
Suzhou 1
Tokyo 1
Zhengzhou 1
Totale 2.028
Nome #
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system 78
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 78
International prognostic scoring system for Waldenstrom macroglobulinemia 76
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 76
Chemoresistance as a function of the pre-therapy tumor burden and the chemotherapy regimen administered. Differences observed with two current chemotherapy regimens for advanced Hodgkin lymphoma 76
The clinical value of tumor burden at diagnosis in Hodgkin lymphoma 72
[Idiopathic myelodysplastic syndromes. A caseload contribution]. 70
Pamidronate versus observation in asymptomatic myeloma: final results with long follow-up of a randomized study 70
Tumor burden in Hodgkin’s lymphoma: much more than the best prognostic factor. 69
New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. 68
Metabolic tumour volumes measured at staging in lymphoma: Methodological evaluation on phantom experiments and patients 68
The prognosis of patients with liver metastases from colorectal cancer still depends on anatomical presentation more than on treatments 68
R-CHOP vs. R-mini-CEOP for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL). 65
A plea to overcome th concept of "staging" and related inadequacy in multiple myeloma. 64
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 63
Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters 63
Changing clinical presentation of multiple myeloma. 63
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 63
Long-term follow-up analysis of HD9601 trial comparing ABVD vs. Stanford V vs. MOPPEBVCAD in patients with newly diagnosed advanced-stage Hodgkin lymphoma. A study from the Intergruppo Italiano Linfomi (IIL). 62
Long-term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with ProMECE-CytaBOM plus involved-field radiation therapy: a study of the Gruppo Italiano Studio Linfomi. 62
Tumor burden predicts treatment resistance in patients with early unfavorable or advanced-stage Hodgkin Lymphoma treated with ABVD and radiotherapy. 61
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. 61
Intestinal T-cell lymphoma with enteropathy-associated T-cell lymphoma-like features arising in the setting of adult autoimmune enteropathy 61
Improving the AJCC/TNM Classification for use in early gastric cancer 60
Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs. 59
International prognostic scoring system for Waldenstrom macroglobulinemia. 59
Tumor burden at diagnosis is the main clinical predictor of cell resistance in patients with early-stage, favorable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. 57
Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells 57
A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses. 55
Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact 55
What has happened to VBM (vinblastine, bleomycin and methotrexate) chemotherapy for early-stage Hodgkin lymphoma ? 54
Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study 54
Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma. 51
Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation 51
Prognostic validation of the international classification of immunoglobulin M gammopathies: A survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? 51
How I treat enteropathy-associated T-cell lymphoma 50
Erratum to: Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study (Intern Emerg Med, (2014), 9, (861-870), DOI 10.1007/s11739-014-1096-1) 50
Chronic granulocytic leukemia. A retrospective study of 91 cases. I. Hemogram at diagnosis and research of prognostic factors. 50
Hodgkin lymphoma. 48
Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes 46
Osteonecrosi avascolare del massiccio facciale in corso di terapia con bisfosfonati [Avascular jaw osteonecrosis associated with bisphophonate therapy]. 45
Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy. 45
Reed-Sternberg cell leukaemia. 43
The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer 42
Natural history of idiopathic refractory sideroblastic anemia. 38
Low incidence but poor prognosis of complicated coeliac disease in four Italian centres. 38
Prognostic factors in symptomatic Waldenstrom's macroglobulinemia 37
Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility 28
Prognostic factors in non-Hodgkin's lymphomas 26
Totale 2.806
Categoria #
all - tutte 11.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.636


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020191 0 0 0 0 0 31 6 33 1 75 45 0
2020/2021314 42 27 4 30 2 40 3 52 13 51 40 10
2021/2022240 5 3 2 4 7 2 6 15 6 11 40 139
2022/2023790 76 76 9 67 81 76 2 56 316 6 16 9
2023/2024235 44 39 10 17 19 56 3 28 1 5 4 9
2024/2025161 33 51 20 16 25 16 0 0 0 0 0 0
Totale 2.806